The NCCN 8th Annual Congress: Hematologic Malignancies™ took place September 20 – 21, 2013 in New York, NY.
Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.
There is no fee for these educational activities.
These activities are approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. Complete accreditation details are provided at the beginning of the individual activities.
Supported by educational grants from Genentech USA, Inc.; Janssen Biotech, Inc., administered by Janssen Services, LLC.; Jazz Pharmaceuticals, Inc.; Millennium: The Takeda Oncology Company; Onyx Pharmaceuticals, Inc.; and Sigma-Tau Pharmaceuticals, Inc.
Click the title of an activity below to proceed.